Key Facts

Invested since 2020
Based in International

About the company

Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. The endocannabinoid system is a key neuromodulator system in the CNS involved in regulating various physiological and cognitive processes. Synendos’ newly developed selective endocannabinoid reuptake inhibitors (SERIs) act by increasing the levels of endogenous cannabinoids in a self-limiting mode of action, representing an innovative and potentially safer therapeutic approach to CNS disorders associated with anxiety, mood and stress-related disorders.

Do you want to

know more about this company?

Zum Artikel

Dr. Laura Pedroza Senior Investment Manager

Dr. Laura PedrozaSenior Investment Manager

Synendos Therapeuthics in the news

Zum Artikel

News

12. November 2020

Synendos Therapeutics Raises CHF 20 Million in Series A Financing

More startups from Life Sciences